Allergen-specific immunotherapy is the only causal treatment for allergic disorders and is effective for aeroallergens (e.g. pollen), food ingredients and hymenoptera venom allergy (bee/wasp). However, the grade of clinical efficacy to date is only about 30% and severe side-effects can occur.
This project has lead to filing of a new therapeutic patent. More information will follow soon.
Currently we are developing methodologies to identify alternative therapy options for the treatment of allergic diseases:
Preclinical models of specific immunotherapy
Discover our preclinical models of specific immunotherapy with tolerance-inducing adjuvants